NORADRENALINE CONTRACTIONS OF HUMAN PROSTATE MEDIATED BY ALPHA(1A)-ADRENOCEPTOR (ALPHA(1C)-)ADRENOCEPTOR SUBTYPE

被引:141
作者
MARSHALL, I [1 ]
BURT, RP [1 ]
CHAPPLE, CR [1 ]
机构
[1] ROYAL HALLAMSHIRE HOSP,DEPT UROL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
关键词
ALPHA(1)-ADRENOCEPTOR SUBTYPES; HUMAN PROSTATE; CHLORETHYLCLONIDINE; WB; 4101; 5-METHYL-URAPIDIL; PHENTOLAMINE; BENOXATHIAN; SPIPERONE; INDORAMIN; BMY; 7378;
D O I
10.1111/j.1476-5381.1995.tb15001.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The subtype of alpha(1)-adrenoceptor mediating contractions of human prostate to noradrenaline was characterized by use of a range of competitive and non-competitive antagonists. 2 Contractions of the prostate to either noradrenaline-(pD(2) 5.5), phenylephrine (pD(2) 5.1):or methoxamine (pD(2) 4.4) were unaltered by the presence of neuronal and extraneuronal uptake blockers; Noradrenaline was about 3 and 10 times more potent than phenylephrine and methoxamine respectively. Phenylephrine and methoxamine were partial agonists. 3 Pretreatment with the alkylating agent, chlorethylclonidine (10(-4) M) shifted the noradrenaline concentration-contraction curve about 3 fold to the right and depressed the maximum response by 31%. This shift is 100 fold less than that previously shown to be produced by chlorethylclonidine; under the Same conditions on alpha(1B)-adrenoceptor-mediated contractions; 4 Cumulative concentration-contraction curves for noradrenaline were competitively antagonized by WE 4101 (pA(2) 9.0), 5-methyl-urapidil (pA(2) 8.6), phentolamine (pA(2) 7.6), benoxathian (pA(2) 8.5), spiperone (pA(2) 7.3), indoramin (pA(2) 8.2) and BMY 7378 (pA(2) 6.6). These values correlated best with published pK(i) values for their displacement of [H-3]-prazosin binding on membranes expressing cloned alpha 1(c)-adrenoceptors and poorly with values from cloned alpha(1b)- and alpha(1d)-adrenoceptors. 5 The good correlation between the functional data on the prostate and the binding data on the expressed alpha(1c)-subtype clone for the affinities of the competitive antagonists suggests that they are the same subtype. As the expressed alpha(1c)-adrenoceptor clone corresponds to the alpha(1A)-adrenoceptor expressed in tissues, contraction of the human prostate to noradrenaline is therefore mediated by an alpha(1A)-adrenoceptor.
引用
收藏
页码:781 / 786
页数:6
相关论文
共 41 条
[1]   INVESTIGATION OF THE SUBTYPES OF ALPHA-1-ADRENOCEPTOR MEDIATING CONTRACTIONS OF RAT AORTA, VAS-DEFERENS AND SPLEEN [J].
ABOUD, R ;
SHAFII, M ;
DOCHERTY, JR .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 (01) :80-87
[2]   SOME QUANTITATIVE USES OF DRUG ANTAGONISTS [J].
ARUNLAKSHANA, O ;
SCHILD, HO .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1959, 14 (01) :48-58
[3]   MOLECULAR-CLONING AND SEQUENCING OF A CDNA-ENCODING A HUMAN ALPHA(1A) ADRENERGIC-RECEPTOR [J].
BRUNO, JF ;
WHITTAKER, J ;
SONG, JF ;
BERELOWITZ, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 179 (03) :1485-1490
[4]  
BURT RP, 1995, IN PRESS BR J PHARM
[5]  
BYLUND DB, 1994, PHARMACOL REV, V46, P121
[6]   PLACEBO-CONTROLLED DOUBLE-BLIND-STUDY OF EFFECT OF PHENOXYBENZAMINE IN BENIGN PROSTATIC OBSTRUCTION [J].
CAINE, M ;
PERLBERG, S ;
MERETYK, S .
BRITISH JOURNAL OF UROLOGY, 1978, 50 (07) :551-554
[7]   ADRENERGIC AND CHOLINERGIC RECEPTORS IN HUMAN PROSTATE, PROSTATIC CAPSULE AND BLADDER NECK [J].
CAINE, M ;
RAZ, S ;
ZEIGLER, M .
BRITISH JOURNAL OF UROLOGY, 1975, 47 (02) :193-202
[8]   A 12-WEEK PLACEBO-CONTROLLED STUDY OF PRAZOSIN IN THE TREATMENT OF PROSTATIC OBSTRUCTION [J].
CHAPPLE, CR ;
CHRISTMAS, TJ ;
MILROY, EJG .
UROLOGIA INTERNATIONALIS, 1990, 45 :47-55
[9]   CHARACTERIZATION OF HUMAN PROSTATIC ADRENOCEPTORS USING PHARMACOLOGY RECEPTOR-BINDING AND LOCALIZATION [J].
CHAPPLE, CR ;
AUBRY, ML ;
JAMES, S ;
GREENGRASS, PM ;
BURNSTOCK, G ;
TURNERWARWICK, RT ;
MILROY, EJG ;
DAVEY, MJ .
BRITISH JOURNAL OF UROLOGY, 1989, 63 (05) :487-496
[10]   RELATIONSHIP BETWEEN ALPHA-ADRENOCEPTOR OCCUPANCY AND CONTRACTILE RESPONSE IN RAT VAS-DEFERENS - EXPERIMENTAL AND THEORETICAL-ANALYSIS [J].
DIAZTOLEDO, A ;
MARTI, MC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 156 (03) :315-324